FDA won't review Afrezza until July

Share this article:

MannKind is going to have to wait a little longer to find out its regulatory fate: the FDA has pushed off its review decision of the inhaled insulin Afrezza for another three months.

The company said in a statement on Monday that the FDA wants more time to review the application. Barron's reports that this is not a surprise for Cowen analysts Simos Simeonidis and Yatin Suneja, both of whom expect the regulator to approve the diabetes medication “in great part because of what is viewed as a ‘real need' for specific patient groups,” they said.

An FDA advisory panel endorsed the drug last week, surprising many, both because of the drug assessments posted online before the panel convened, and the fact that the FDA had already rejected the drug three times.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.